AI Launch Profile
Introducing GPT-Rosalind for life sciences research
OpenAI introduced GPT-Rosalind, a purpose-built frontier reasoning model for biology, drug discovery, translational medicine, and scientific workflows.
At a glance
Launch Snapshot
- Company
- OpenAI
- Launch date
- April 16, 2026
- Launch type
- Model Release
- Category
- AI Infrastructure, AI Research Tools
- Audience
- Developers, Enterprises, Researchers
- Pricing
- Research preview access is available through OpenAI trusted access for qualified customers; during the preview, use does not consume existing credits or tokens subject to abuse guardrails.
- Free plan
- No
- API
- Yes
- Open weights/source
- No
Launch Context
Use these links to move from this record into the broader Launch Intelligence database.
Verification & Sources
- Evidence state
- Recheck due
- Source links
- 2
- Freshness
- Needs recheck: checked June 8, 2026
- Last updated
- June 11, 2026
What this evidence state means
- Definition
- The claim was previously checked, but its review window expired or a material change may have invalidated it.
- Required provenance
- The prior evidence and check date are retained, together with the expiry or change signal that triggered recheck.
- Owner
- Kingy freshness queue owner and assigned editorial reviewer
- Freshness rule
- This is already outside its freshness rule. It must not be presented as current until reviewed against current evidence.
- Disputes and corrections
- Use “Suggest a correction” on the record. Kingy editorial reviews the cited evidence, records material corrections, and changes or removes the state when it is not supported.
Key source checks
Suggest a correction
Kingy Launch Score
6.4 / 10 · Mixed
One earned credibility score, computed from cited evidence — not a placeholder. How the Kingy Launch Score works
Why this score
- Source & verification 7.5/10 — The launch post plus a Help Center overview — dated, single-vendor sourcing. openai.com
- Product evidence 5.0/10 — A research preview gated behind OpenAI trusted access for qualified customers — not openly testable. help.openai.com
- Significance & novelty 8.0/10 — A purpose-built frontier reasoning model for biology, drug discovery, and translational medicine — significant domain specialization. openai.com
- Traction signals not scored — insufficient sourced evidence
- Offer clarity 5.0/10 — Preview access documented as not consuming existing credits, subject to abuse guardrails; no public pricing exists at this stage. help.openai.com
Evidence checked 2026-07-10
Creator Coverage Next Steps
This launch has signals that may support demos, reviews, creator education, founder storytelling, or practical product explainers.
Launching an AI product that needs clear demos, creator education, and buyer trust? Sponsor a Kingy AI video or launch feature.
Kingy AI Take
OpenAI introduced GPT-Rosalind, a purpose-built frontier reasoning model for biology, drug discovery, translational medicine, and scientific workflows (openai.com). Qualified Life Sciences Organizations, Biotech Teams, and Research Institutions can apply through trusted access, with preview use not consuming existing credits. It is a gated research preview rather than a public product, so treat capability claims as OpenAI-reported until your own scientists can evaluate it.
Who it is for
Qualified life sciences organizations, biotech and pharmaceutical teams, research institutions, and scientific developers working on biology-heavy workflows.
Traction notes
Domain-specific frontier models matter for the hub because buyers are moving from general chat models toward specialized systems for regulated workflows.
Source list
Sources
Related Kingy Links
Editorial submissions and sponsor-fit reviews are separate. Payment does not influence Kingy scores, verdicts, rankings, evidence labels, or publication decisions.